Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEFAZOLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEFAZOLIN.
CECLOR CD vs Cefazolin
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily in susceptible gram-positive bacteria.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
1-2 g IV/IM every 6-8 hours; maximum 12 g/day.
None Documented
None Documented
Clinical Note
moderateCefazolin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefazolin."
Clinical Note
moderatePhenytoin + Cefazolin
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
1.8 hours in normal renal function; extends to 30–70 hours in end-stage renal disease (CrCl <10 mL/min).
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary: <1%; fecal: negligible.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The protein binding of Cefazolin can be decreased when combined with Phenytoin."